- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, June 28, 2019
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
America’s Health Insurance Plans' Monday Accountable Care SmartBrief included an article from The American Journal of Managed Care® (AJMC®). The article, “Analysis Finds Progress in Reducing Progress on Low-Value Services Positive but Sluggish,” covered an analysis of spending on low- and high-value care from 2014 to 2016 and found that despite significant discussion about reducing low-value care, reduction has been slight.
The National Pharmaceutical Council’s Monday CER Daily Newsfeed included an article from AJMC®’s sister site The Center for Biosimilars®. The article, “Real-World Evidence Shows Switching Among ESAs in CKD Is Not Associated With Risks to Safety, Efficacy,” reported that no statistically significant risk in terms of lack of effectiveness or safety was found for patients who switched therapies versus those who remained on their first therapy in either the reference group or the biosimilar group.
Tuesday’s CER Newsfeed included AJMC®’s interview with Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders, in which he discussed factors that have historically been underrepresented in value assessment frameworks for rare disease therapies.
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Muscle-Directed Therapy Apitegromab Meets Primary End Point in Phase 3 SAPPHIRE Trial of SMA
October 17th 2024Patients aged 2-21 receiving apitegromab showed clinically meaningful motor function improvements, with a favorable safety profile consistent with long-term data, as Scholar Rock prepares for US and EU regulatory submissions in Q1 2025.
Read More
